Cystadenocarcinoma
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Cystadenocarcinoma, Mucinous
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
Cystadenoma
Cystadenocarcinoma, Papillary
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
Cystadenoma, Mucinous
Mucocele
Cysts
Pyonephrosis
Mixed Tumor, Mesodermal
Ovarian Neoplasms
Biliary Tract Neoplasms
Barium Sulfate
Pseudomyxoma Peritonei
A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Bile Ducts, Intrahepatic
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Tomography, X-Ray Computed
Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/526)
The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type. (+info)The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. (2/526)
The CCAAT/enhancer binding protein (C/EBP) family of transcription factors is involved in metabolism and differentiation of cells, especially in rodent liver cells and adipocytes. Their roles in vivo and in particular during pathophysiological conditions in humans are largely unknown. We have investigated the presence of C/EBPalpha, -beta, -delta and -zeta in normal ovaries and in epithelial ovarian tumours of different stages. Immunohistochemical experiments demonstrated that C/EBPalpha and C/EBPbeta were preferentially expressed in epithelial/tumour cells irrespective of stage or grade of the tumour. C/EBPbeta was located in the nuclei of the cells, in contrast to C/EBPalpha, which was present only in the cytoplasm of these cells. The nuclear localization of C/EBPbeta indicates an active role of this transcription factor in tumour cells, whereas the cytoplasmic distribution suggests a more passive function of C/EBPalpha. C/EBPdelta and -zeta demonstrated a more diverse distribution with predominant localization to epithelial cells, but stromal distribution was also noted. The intracellular distribution was confined to both the nucleus and the cytoplasm for C/EBPdelta and -zeta. Western blotting demonstrated that C/EBPalpha, -beta, -delta and -zeta were present in a majority of the samples. The amount of C/EBPbeta increased markedly with malignancy, i.e. with degree of dedifferentiation, while the other members of the C/EBP family displayed a more constant expression level. These results demonstrate an association between the expression of members of the C/EBP family and the formation of epithelial ovarian tumours, with C/EBPbeta as a potential marker for these tumours. As C/EBPbeta is known to be expressed during proliferation of cells in vitro, it may participate in the proliferative process of ovarian epithelial tumour cells in vivo and play a central role in tumour progression. (+info)Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (3/526)
Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer. (+info)Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. (4/526)
Between 1976 and 1996, 176 borderline ovarian tumours were registered in the Cancer Registry of the Swiss canton of Vaud, corresponding to an age-adjusted incidence (world standard) of 2.7 in 100,000. Incidence rose from 1.7 per 100,000 during 1976-81 to 2.7 per 100,000 during 1987-91, and then levelled off; 58% of cases were serous and 41% mucinous. Relative survival was 94% at 10 years; 18 second neoplasms were observed, compared with 10.3 expected, and there was a significant excess of invasive ovarian cancers (four observed, including three synchronous, compared with 0.4 expected). (+info)Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. (5/526)
AIM: To determine whether three-dimensional power Doppler can improve the recognition of pelvic tumor morphology and angiogenesis. METHODS: Using this technique we analyzed 180 adnexal masses and 110 uterine lesions. Tumor volume, morphology, and vascularity were evaluated in each patient. Irregular and randomly dispersed vessels with complex branching depicted by comprehensive three dimensional display were suggestive of pelvic malignancy, while linear-like vascular morphology, single vessel arrangement and regular branching were typical for benign structures. RESULTS: Addition of qualitative analysis of vascular architecture of adnexal tumor to morphological parameters reached 96.15% sensitivity and 98.73% specificity. When endometrial lesions were prospectively analyzed, sensitivity and specificity were 91.67% and 98.49%, respectively. Because the lowest positive predictive value of 16.67% was obtained for myometrial lesions, this method should not be advised for their eva luation. CONCLUSION: Good results achieved by three dimensional ultrasound can be explained by improved recognition of the pelvic lesion anatomy, characterization of the surface features, detection of the tumor infiltration, and precise depiction of the size and volume. Three dimensional power Doppler imaging can detect structural abnormalities of the malignant tumor vessels, such as arteriovenous shunts, microaneurysms, tumoral lakes, disproportional calibration, coiling, and dichotomous branching. Therefore it enhances and facilitates the morphologic and functional evaluation of both benign and malignant pelvic tumors. (+info)Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/526)
Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not. (+info)Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. (7/526)
The purpose of this study was to investigate the frequency of p53 overexpression in the primary ovarian tumors of patients with stages II and III serous borderline tumors (SBTs) and to determine the relationship between p53 overexpression and risk of progression/recurrence and survival. Of 112 patients with stages II-IV SBTs, paraffin-embedded tissue from the primary ovarian tumor was available in 68 cases. Immunohistochemical staining for p53 was performed. Clinical information was abstracted from the medical records. The major end points selected for analysis were time to progression/relapse, disease-free survival, overall survival, and cause-specific survival. Univariate and multivariate regression analyses were also performed. The median patient age was 37 years (range, 17-67 years). Twenty-two patients had stage II disease, and 46 had stage III disease. The mean follow-up time was 105 months. Nineteen patients (28%) had either disease progression (1 patient) or relapse (18 patients). Eleven patients died: 10 patients died of their tumor, and 1 patient died of other causes. Thirteen cases (19%) had positive immunostaining for p53. Overexpression of p53 was significantly associated with an increased probability of progression/recurrence (P = 0.005) and a decreased overall survival (P = 0.012). After adjusting for age, International Federation of Gynecology and Obstetrics (FIGO) stage, the presence of residual tumor, and the presence of invasive implants, patients whose tumors overexpressed p53 had a 4-fold increased risk of progression/ recurrence. Similarly, women whose tumor overexpressed p53 had an approximately 6-fold increased risk of death. p53 overexpression in the ovarian tumors of patients with stage II and III SBTs is significantly associated with increased probability of relapse and decreased overall survival. This information should provide better prognostic data to patients and their families and allow us to select patients who might benefit from postoperative treatment. (+info)Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. (8/526)
Allelic deletions of multiple chromosome 17q loci in sporadic ovarian cancer of epithelial origin suggest that inactivation of tumor suppressor gene(s) in these regions may be important for ovarian tumorigenesis. To further define the pattern of allelic imbalance in epithelial ovarian tumors of different histologies, a PCR-based assay was used to assess loss of heterozygosity (LOH) of polymorphic markers representative of TP53, BRCA1, NME1 and GH1, and region 17q23-25. LOH was observed for at least one marker in 68% of malignant tumors (n=60) and in 18% tumors of borderline malignancy (n=11), but not in benign tumors (n=5). The highest frequency of LOH in malignant tumors (64%) was observed with D17S801 on 17q25. Ten of 39 malignant ovarian tumors displaying LOH of at least one 17q marker, displayed a LOH pattern enabling the determination of a minimal region of overlapping deletion defined by D17S795 and D17S801. One borderline tumor also displayed an interstitial LOH pattern that overlapped this 17q25 minimal region of deletion. The histologies of malignant tumors displaying a pattern indicative of interstitial 17q deletions were of the endometrioid, clear cell and mucinous epithelial types. As the minimal region of overlap defined by these tumors overlap regions deleted in malignant tumors of all histologic types, and in a tumor of borderline malignancy, the 17q25-tumor suppressor may be implicated in the development of all types of epithelial ovarian tumors. (+info)
GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
Malignant Ovarian Serous Tumor - My Cancer Genome
TP53 Gene Mutation Found in 80% of High Grade Ovarian Serous Carcinomas; TP53 Not Directly Involved In The Development of Drug...
Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis<...
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than...
Dishevelled family proteins in serous ovarian carcinomas: A clinicopathologic and molecular study
Uterine Serous Carcinoma
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma | BMC Cancer | Full Text
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. - Cancer Epidemiology Unit (CEU)
Molecular Characterization of an Intact p53 Pathway Subtype in High-Grade Serous Ovarian Cancer
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Preservation of stemness in high-grade serous ovarian cancer organoids requires low Wnt environment - EGA European Genome...
TBX2 expression is associated with platinum‑sensitivity of ovarian serous carcinoma
Events Archive - ISGyP
Plus it
Plus it
Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study
Benign and Low Grade Serous Epithelial Tumors: Recent Developments and Diagnostic Problems. - Semantic Scholar
Study Identifies Cells-of-origin of High-grade Serous Ovarian Cancer - OncoZine
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma - pdf descargar
diagnosis of ovarian tumors - Humpath.com - Human pathology
JCI -
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice
GRAF | Cancer Genetics Web
Low Grade Serous Ovarian Cancer - United States
Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma
Ovarian cancer in lymph nodes. Chisturi de giardia în scaunul uman
High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome | Oncotarget
Daniel J. Powell Jr. | Faculty | Center for Research on Reproduction and Womens Health | Perelman School of Medicine at the...
UPENN Biomedical Graduate Studies | Daniel J. Powell Jr.
Plus it
PNNL: BTRR Proteomics Resource - Publications
KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature
Low-grade serous carcinoma (mullerian/ovarian type) of the paratestis presenting as diffuse metastatic disease of unknown...
Outcome after combined modality treatment for uterine papillary serous carcinoma: A study by the Rare Cancer Network (RCN)<...
Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum<...
Cervical Serous Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma - Full Text...
Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma<...
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
Mass spectrometry-based peptidome profiling of human serous ovarian cancer tissues | Bioinformatics Solutions Inc.
Uterine papillary serous carcinoma: A rare type of endometrial carcinoma with worse outcomes-IJOGR-IP Innovative Publication...
Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct...
CAISMOV24, a new human low-grade serous ovarian carcinoma cell line | BMC Cancer | Full Text
Is invasive micropapillary serous carcinoma a low-grade carcinoma?<...
MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous...
uterine serous carcinoma survival rates
Most recent papers with the keyword Uterine serous cancer | Read by QxMD
Uterine Papillary Serous Carcinoma (UPSC): any others here??? | Cancer Survivors Network
Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis...
5 Easy Facts About best provestra review Described
Plus it
Stefanie Ueda, MD | Obstetrics, Gynecology & Reproductive Sciences
Plus it
Michele Cote - Oncology - Wayne State University
Definition and Algorithm | Ovarian Cancer Prevention, Detection and Treatment
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers<...
Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary?
Papillary serous ovarian carcinoma | Case Studies
A Comparison of WT1, PTEN and the AKT Pathway in Ovarian Serous Carcinoma vs. Colorectal Adenocarcinoma - Research Database,...
Plus it
The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review
JCDR - Citation Manager Cite this Article Clinico Pathological Analysis of Uterine Serous Carcinoma in a Cancer Centre from...
Flaviopierleoni » GuestBook
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. - PubMed - NCBI
Reseach reveals genomic similarities between breast cancer, ovarian cancers
CiNii Articles - Yoshinaga Kousuke
Ovarian Cancer Development and Metastasis - ScienceOpen
A Study Combining the Peposertib (M3814) Pill with Standard Chemotherapy in Patients with Ovarian Cancer with an Expansion in...
Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer...
My Faux Eyebrows
Tumor apelin immunoreactivity is correlated with body mass index in ovarian high grade serous carcinoma. | AVESİS
Serous cystadenocarcinoma
... is a type of tumor in the cystadenocarcinoma grouping. Most commonly, the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-187. doi:10.1097/ ... King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report ... with the majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous ...
Papillary serous cystadenocarcinoma
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. Papillary serous cystadenoma Kosary CL ( ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ...
Ovarian serous cystadenoma
"Ovarian serous cystadenocarcinoma". , Radiology Reference Article. Radiopaedia.org. Retrieved 2019-09-21. v t e v t e (Articles ... Serous ovarian cystadenocarcinomas account for ~25% of serous tumours. Ovarian cancer Pancreatic serous cystadenoma Serous ... also called serous borderline tumours, that may transform into serous carcinoma. Serous cystadenomas (of the ovary) are not ... Ovarian serous cystadenoma, also (less precisely) known as serous cystadenoma, is the most common ovarian neoplasm, ...
Fibroblast growth factor receptor 1
... of ovarian Papillary serous cystadenocarcinoma (almost all amplifications); ~5% of colorectal cancers (~60 amplifications, 40% ...
Cystadenocarcinoma
Bilateral presentation is common with serous cystadenocarcinoma. Papillary serous cystadenocarcinoma Ovarian serous cystadenoma ... "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Journal of Gastrointestinal Surgery. 13 (10 ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular epithelium, in which cystic ... A cystadenocarcinoma contains complex multi-loculated cyst but with exuberant solid areas in places. It usually presents with ...
Pancreatic serous cystadenoma
... "serous cystadenocarcinoma".[citation needed] These lesions rarely require surgery unless they are symptomatic or the diagnosis ... Those that are benign, that have not spread to other organs, are designated "serous cystadenoma". Serous cystadenomas can be ... There are some exceptions; rare case reports have described isolated malignant serous cystadenocarcinomas. In addition, serous ... Pancreatic serous cystadenoma is a benign tumour of pancreas. It is usually found in the tail of the pancreas, and may be ...
Psammoma body
Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary thyroid carcinoma Papillary renal cell carcinoma Ovarian papillary serous cystadenoma and cystadenocarcinoma ... Endometrial adenocarcinomas (Papillary serous carcinoma ~3%-4%) Meningiomas, in the central nervous system Peritoneal and ...
Ovarian cancer
Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to ... Mucinous tumors include mucinous adenocarcinoma and mucinous cystadenocarcinoma. Mucinous adenocarcinomas make up 5-10% of ... Serous carcinomas are thought to begin in the Fallopian tube. High grade serous carcinoma accounts for 75% of all epithelial ... Serous carcinomas may develop from serous tubal intraepithelial carcinoma, rather than developing spontaneously from ovarian ...
SK-OV-3
... ovarian cancer cell line derived from the ascites of a 64-year-old Caucasian female with an ovarian serous cystadenocarcinoma. ...
Leukotriene B4 receptor 2
... the Serous cystadenocarcinoma type of ovarian cancer, and uterine cervical carcinoma. Other studies have implicated BLT2 in ...
Estrogen receptor beta
... ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues". The Journal ...
Surface epithelial-stromal tumor
75% are benign or of borderline malignancy, and 25% are malignant The malignant form of this tumor, serous cystadenocarcinoma, ... lined by tall, columnar, ciliated epithelial cells filled with clear serous fluid the term serous which originated as a ... Malignant serous tumors occur later in life on average, although somewhat earlier in familial cases. 20% of benign, 30% of ... The overall prognosis is somewhat worse than for serous or mucinous tumors, and the 5-year survival rate for patients with ...
List of MeSH codes (C04)
... cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.200.025.540 - ... cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 - cystadenocarcinoma, serous MeSH C04.557.470.590.485 - cystadenoma ... cystadenocarcinoma MeSH C04.557.470.200.025.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 - ... cystadenocarcinoma MeSH C04.557.470.590.480.225 - cystadenocarcinoma, mucinous MeSH C04.557.470.590.480.230 - ...
Pancreatectomy
... mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma Acinar cell ...
International Cancer Genome Consortium
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Serous cystadenocarcinoma Canada: Pancreatic cancer - Ductal adenocarcinoma and prostate cancer - adenocarcinoma China: Gastric ...
International Classification of Diseases for Oncology
NOS Serous cystoma Serous microcystic adenoma M8441/3 Serous cystadenocarcinoma, NOS (C56.9) Serous adenocarcinoma, NOS Serous ... M8460/0 Papillary serous cystadenoma, NOS (C56.9) M8460/3 Papillary serous cystadenocarcinoma (C56.9) Papillary serous ... Serous cystadenofibroma of borderline malignancy M9014/3 Serous adenocarcinofibroma Malignant serous adenofibroma Serous ... M8461/3 Serous surface papillary carcinoma (C56.9) Primary serous papillary carcinoma of peritoneum (C48.1) M8462/1 Serous ...
Testicular cancer
... borderline malignancy Serous carcinoma Well differentiated endometrioid tumor Mucinous cystadenoma Mucinous cystadenocarcinoma ... lymphoma of the testes pediatric-type follicular lymphoma of the testes Carcinoid Tumors of ovarian epithelial types Serous ...
Cystadenoma
ISBN 978-1-4160-2999-1. Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/cystadenocarcinoma at eMedicine v t e ( ... When malignant, it is called cystadenocarcinoma. When not otherwise specified, the ICD-O coding is 8440/0. However, the ... following classifications also exist: serous cystadenoma (8441-8442) papillary cystadenoma (8450-8451, 8561) mucinous ...
The Cancer Genome Atlas
... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ... Three tumor types were explored during the pilot phase, glioblastoma multiforme (GBM) and high-grade serous ovarian ... and ovarian serous adenocarcinoma. In 2009, it expanded into phase II, which planned to complete the genomic characterization ... and exome sequencing of 316 tumor samples of high grade serous ovarian cancer in Nature in June 2011. The researchers found ...
Cystic lesions of the pancreas
Pancreatic serous cystadenoma Pancreatic serous cystadenocarcinoma Pancreatic mucinous cystic tumors (13.4%) Pancreatic ... Pancreatic intraductal papillary mucinous tumors (most common diagnosis - 52.6%) Pancreatic serous cystic tumors (20.6%) ... mucinous cystadenoma Pancreatic mucinous cystadenocarcinoma (Articles needing additional references from January 2017, All ...
Mucinous cystadenoma
Biliary cystadenoma and cystadenocarcinoma constitute less than 5% of intrahepatic cysts originating from the bile duct. ... On an average, mucinous accounts for 40-50% of cystic tumors, and serous cytadenoma accounts for 30% of it. Mucinous ...
2014 Ju-Jitsu World Championships
The 2014 Ju-Jitsu World Championship were the 12th edition of the Ju-Jitsu World Championships, and were held in Paris, France from November 28 to November 30, 2014. 28.11.2014 - Men's and Women's Fighting System, Men's and Women's Jiu-Jitsu (ne-waza), Men's Duo System - Classic 29.11.2014 - Men's and Women's Fighting System, Men's and Women's Jiu-Jitsu (ne-waza), Women's Duo System - Classic 30.11.2014 - Men's Jiu-Jitsu (ne-waza), Mixed Duo System - Classic, Team event Vincent MATCZAK (2014-09-30). "4TH INVITAION TO WORLD CHAMPIONSHIP 2014" (PDF). Retrieved 2019-11-28.[dead link] Online results Official results (PDF) Mixed team event results (PDF) (All articles with dead external links, Articles with dead external links from April 2022, Ju-Jitsu World Championships, 2014 in French sport ...
Bolley Johnson
Bolley L. "Bo" Johnson (born November 15, 1951) is an American politician from the state of Florida. A member of the Democratic Party, Johnson was a member of the Florida House of Representatives, and served as the Speaker of the Florida House of Representatives. Johnson is from Milton, Florida. His father and grandfather served as county commissioners for Santa Rosa County, Florida. Johnson graduated from Milton High School, and became the first member of his family to attend college. He received his bachelor's degree from Florida State University. Johnson volunteered for Mallory Horne when Horne served as the president of the Florida Senate. At the age of 22, Johnson met Lawton Chiles, then a member of the United States Senate, who hired him as a legislative aide in 1973. Johnson was elected to the Florida House of Representatives, representing the 4th district from November 7, 1978 to November 3, 1992. He also served the 1st district from November 3, 1992 to November 8, 1994. He became the ...
Don't Say No
... may refer to: Don't Say No (Billy Squier album), a 1981 album by American rock singer Billy Squier, and its title track Don't Say No (Seohyun EP), a 2016 extended play by South Korean pop singer Seohyun, and its title track "Don't Say No" (Tom Tom Club song), from the 1988 album Boom Boom Chi Boom Boom "Don't Say No", by Robbie Williams from the 2005 album Intensive Care "Don't Say No Tonight", a 1985 single by Eugene Wilde This disambiguation page lists articles associated with the title Don't Say No. If an internal link led you here, you may wish to change the link to point directly to the intended article. (Disambiguation pages with short descriptions, Short description is different from Wikidata, All article disambiguation pages, All disambiguation pages, Disambiguation pages ...
Dewoitine D.371
The Dewoitine 37 was the first of a family of 1930s French-built monoplane fighter aircraft. The D.37 was a single-seat aircraft of conventional configuration. Its fixed landing gear used a tailskid. The open cockpit was located slightly aft of the parasol wing. The radial engine allowed for a comparatively wide fuselage and cockpit. Design of this machine was by SAF-Avions Dewoitine but owing to over work at that companies plant at the time, manufacture of the D.37/01 was transferred to Lioré et Olivier. They were high-wing monoplanes of all-metal construction with valve head blisters on their engine cowlings. The first prototype flew in October 1931. Flight testing resulted in the need for multiple revisions in both engine and airframe, so it was February 1934 before the second prototype flew. Its performance prompted the French government to order for 28 for the Armée de l'Air and Aéronavale. The Lithuanian government ordered 14 that remained in service with their Air Force until 1936, ...
Noor-ul-Ain
The Noor-ul-Ain (Persian: نور العين, lit. 'the light of the eye') is one of the largest pink diamonds in the world, and the centre piece of the tiara of the same name. The diamond is believed to have been recovered from the mines of Golconda, Hyderabad in India. It was first in possession with the nizam Abul Hasan Qutb Shah, later it was given as a peace offering to the Mughal emperor Aurangazeb when he defeated him in a siege. It was brought into the Iranian Imperial collection after the Persian king Nader Shah Afshar looted Delhi in the 18th century.[citation needed] The Noor-ul-Ain is believed to have once formed part of an even larger gem called the Great Table diamond. That larger diamond is thought to have been cut in two, with one section becoming the Noor-ul-Ain and the other the Daria-i-Noor diamond. Both of these pieces are currently part of the Iranian Crown Jewels. The Noor-ul-Ain is the principal diamond mounted in a tiara of the same name made for Iranian Empress Farah ...
Benoist Land Tractor Type XII
The Benoist Land Tractor Type XII was one of the first enclosed cockpit, tractor configuration aircraft built. Benoist used "Model XII" to several aircraft that shared the same basic engine and wing design, but differed in fuselage and control surfaces. The Type XII was a tractor-engined conversion of the model XII headless pusher aircraft that resembled the Curtiss pusher aircraft. Demonstration pilots used Benoist aircraft to demonstrate the first parachute jumps, and the tractor configuration was considered much more suitable for the task. The first example named the "Military Plane" had a small box frame covered fuselage that left the occupants mostly exposed to the wind. The later model XII "Cross Country Plane" had a full fuselage that occupants sat inside of. The first tractor biplane used a wooden fuselage with a small seat on top. The wings were covered with a Goodyear rubberized cloth. The first model XII was built in the spring of 1912. On 1 March 1912, Albert Berry used a headless ...
Santa Cruz Barillas
... (also known as Yalmotx in Qʼanjobʼal) is a town, with a population of 17,166 (2018 census), and a municipality in the Guatemalan department of Huehuetenango. It is situated at 1450 metres above sea level. It covers a terrain of 1,174 km². The annual festival is April 29-May 4. Barillas has a tropical rainforest climate (Af) with heavy to very heavy rainfall year-round and extremely heavy rainfall from June to August. Citypopulation.de Population of departments and municipalities in Guatemala Citypopulation.de Population of cities & towns in Guatemala "Climate: Barillas". Climate-Data.org. Retrieved July 26, 2020. Muni in Spanish Website of Santa Cruz Barillas Coordinates: 15°48′05″N 91°18′45″W / 15.8014°N 91.3125°W / 15.8014; -91.3125 v t e (Articles with short description, Short description is different from Wikidata, Pages using infobox settlement with no coordinates, Articles containing Q'anjob'al-language text, Coordinates on Wikidata, ...
Maria Margaret Pollen
Maria Margaret La Primaudaye Pollen (10 April 1838 - c. 1919), known as Minnie, was a decorative arts collector. As Mrs John Hungerford Pollen, she became known during the early-twentieth century as an authority on the history of textiles, publishing Seven Centuries of Lace in 1908. Maria Margaret La Primaudaye was born into a Huguenot family on 10 April 1838, the third child of the Revd Charles John La Primaudaye, a descendant of Pierre de La Primaudaye. She was educated in Italy. Her family converted to Catholicism in 1851, and it was in Rome that her father met another recent English convert, John Hungerford Pollen, previously an Anglican priest and a decorative artist. She became engaged to Pollen, who was then seventeen years her senior, in the summer of 1854, and was married in the church of Woodchester monastery, near Stroud, Gloucester, on 18 September 1855. The Pollens initially settled in Dublin, where John Hungerford Pollen had been offered the professorship of fine arts at the ...
Ronald Fogleman
Ronald Robert Fogleman (born January 27, 1942) is a retired United States Air Force general who served as the 15th Chief of Staff of the Air Force from 1994 to 1997 and as Commanding General of the United States Transportation Command from 1992 to 1994. A 1963 graduate from the United States Air Force Academy, he holds a master's degree in military history and political science from Duke University. A command pilot and a parachutist, he amassed more than 6,800 flying hours in fighter, transport, tanker and rotary wing aircraft. He flew 315 combat missions and logged 806 hours of combat flying in fighter aircraft. Eighty of his missions during the Vietnam War were as a "Misty FAC" in the F-100F Super Sabre at Phù Cát Air Base, South Vietnam between 25 December 1968 and 23 April 1969. Fogleman was shot down in Vietnam in 1968, while piloting an F-100. He was rescued by clinging to an AH-1 Cobra attack helicopter that landed at the crash site. In early assignments he instructed student pilots, ...
Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma
| Bangladesh Journal of...
Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma Authors. * Sanjay Sengupta Associate ... collision tumor, dysgerminoma, serous cystadenocarcinoma Abstract. Collision tumors of ovary are rare neoplasms and most ... Combination of papillary serous cystadenocarcinoma and dysgerminoma was yet to be reported. A twenty years female patient ... Microscopically it was diagnosed as a collision tumor of ovary composed of dysgerminoma and serous cystadenocarcinoma. Mixed ...
IMSEAR at SEARO: Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma.
Microscopically it was diagnosed as a collision tumor of ovary composed of dysgerminoma and serous cystadenocarcinoma. Mixed ... Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma. ... a rare combination of dysgerminoma and serous cystadenocarcinoma. Bangladesh Journal of Medical Science. 2014; 13(2): 224-227. ... Combination of papillary serous cystsdenocarcinoma and dysgerminoma was yet to be reported. A twenty years female patient ...
TMEM158 promotes the proliferation and migration of glioma cells via STAT3 signaling in glioblastomas | Cancer Gene Therapy
Evaluating cell lines as tumour models by comparison of genomic profiles
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma - Full Text View - ClinicalTrials.gov
Cystadenocarcinoma, Serous. Neoplasms, Glandular and Epithelial. Neoplasms by Histologic Type. Neoplasms. Cystadenocarcinoma. ... A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO). The safety and scientific validity of this study is ... Neoplasms, Cystic, Mucinous, and Serous. Adavosertib. Enzyme Inhibitors. Molecular Mechanisms of Pharmacological Action. ... in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum- ...
CN113168886A - 用于使用神经网络进行种系和体细胞变
Pancreatic Pseudocysts: Practice Essentials, Background, Pathophysiology
Cholangiocarcinoma
The Role of CBLL1 in the Prognosis and Immune Infiltration of Pan-Cancer | Research Square
Cells | Free Full-Text | Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding...
Find Research outputs - Manipal Academy of Higher Education, Manipal, India
MRI classification and characterization of complex ovarian masses
1 Given their varied imaging appearance these malignancies have overlapping features with serous cystadenocarcinoma, as both ... Serous cystadenocarcinomas, the malignant variant of the serous epithelial neoplasm, are among the high-grade cancers seen in ... Serous cystadenomas are benign epithelial tumors seen in the 4th to 5th decade. Generally smaller than mucinous tumors, these ... They are larger than serous neoplasms, with a "honey-comb" of locules with varied signal intensities separated by thin ...
Simple Ovarian Cysts on Ultrasound Need No Further Monitoring
Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery
... mucinous cystadenocarcinoma; AVC: ampulla of Vater carcinoma; DBDC: distal bile duct carcinoma; IPMN: intraductal papillary ... serous cystadenomas or pancreatic pseudocysts) or histologically confirmed malignant pancreatic tumors, including ductal ... adenocarcinoma, neuroendocrine tumors, and mucinous cystadenocarcinoma; 15 patients with biliary carcinoma, inconclusive ...
Ovarian collision tumor consisting of sclerosing stromal tumor and mature cystic teratoma complicated with Meigs syndrome: A...
Ovarian serous cystadenoma usually deteriorates to form serous cystadenocarcinoma, which has distinct papillary protrusions on ... Bige O, Demir A, Koyuncuoglu M, Secil M, Ulukus C and Saygili U: Collision tumor: Serous cystadenocarcinoma and dermoid cyst in ... Seo EJ, Kwon HJ and Shim SI: Ovarian serous cystadenoma associated with Sertoli-Leydig cell tumor-a case report. J Korean Med ... Serous cystadenomas are smaller than mucinous cystadenomas, but they frequently have calcifications and papillary soft tissue ...
HuGE Navigator|HuGE Literature Finder|PHGKB
Serum vitamin D deficiency and risk of epithelial ovarian cancer in Lagos, Nigeria - ecancer
Prognostic and immune regulating roles of YIF1B in Pan-Cancer: a potential target for both survival and therapy response...
... ovarian serous cystadenocarcinoma (OV), skin cutaneous melanoma (SKCM) and uveal melanoma (UVM), among which YIF1B had the ... D) DSS difference between groups in ovary serous cystuadenocarcinoma (OV). (E) DSS difference between groups in KIRC. (F) DSS ... D) DSS difference between groups in ovary serous cystuadenocarcinoma (OV). (E) DSS difference between groups in KIRC. (F) DSS ...
Female reproductive system Archives | USMLE XL
FFCP PHASE1:Hg19::chr3:197205905..197205924,+ - resource browser
serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.22. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ... serous adenocarcinoma cell line:JHOS-2.CNhs11746.10639-108I9. 0.00. serous adenocarcinoma cell line:SK-OV-3-R after co-culture ... mucinous cystadenocarcinoma cell line:MCAS.CNhs11873.10784-110H1. 0.00. mycosis fungoides, T cell lymphoma cell line:HuT 102 ... serous adenocarcinoma cell line:SK-OV-3-R, biol_rep1.CNhs13099.11841-124H5. 1.91. ...
FFCP PHASE2:Hg19::chr6:71665623..71665630,- - resource browser
serous cystadenocarcinoma cell line:HTOA.CNhs11827.10693-109F9. 0.00. signet ring carcinoma cell line:Kato III.CNhs10753.10436- ... serous adenocarcinoma cell line:JHOS-2.CNhs11746.10639-108I9. 0.00. serous adenocarcinoma cell line:SK-OV-3-R after co-culture ... mucinous cystadenocarcinoma cell line:MCAS.CNhs11873.10784-110H1. 0.00. mycosis fungoides, T cell lymphoma cell line:HuT 102 ... serous adenocarcinoma cell line:SK-OV-3-R, biol_rep1.CNhs13099.11841-124H5. 0.00. ...
BMB Reports
Ubiquitin-specific peptidase 37: an important cog in the oncogenic machinery of cancerous cells | Journal of Experimental &...
MeSH Browser
Cystadenocarcinoma, Papillary [C04.557.470.200.025.480.230] * Cystadenocarcinoma, Serous [C04.557.470.200.025.480.240] ... Cystadenocarcinoma [C04.557.470.590.480] * Cystadenocarcinoma, Mucinous [C04.557.470.590.480.225] * Cystadenocarcinoma, ... Cystadenocarcinoma [C04.557.470.200.025.480] * Cystadenocarcinoma, Mucinous [C04.557.470.200.025.480.225] * ... Cystadenocarcinoma Preferred Term Term UI T010250. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1966). ...
HuGE Navigator|Genopedia|PHGKB
Code System Concept
DeCS
Cystadenocarcinomas, Serous. Serous Cystadenocarcinoma. Serous Cystadenocarcinomas. Tree number(s):. C04.557.470.200.025.480. ... Cystadenocarcinoma, Serous - Preferred Concept UI. M0027515. Scope note. A malignant cystic or semicystic neoplasm. It often ... patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma ... patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma ...
Search | African Index Medicus (AIM)
The Cancer Gene Index Gene-Disease and Gene-Compound XML Documents - ICR - Cancer Gene Index - NCI Wiki
... ovarian serous cystadenocarcinoma and ovarian serous papillary adenocarcinoma and the parent terms malignant ovarian serous ... ovarian serous adenocarcinoma), and click the Search button (3). If you need help finding your gene, disease, or compound term ... tumor, ovarian adenocarcinoma, and serous adenocarcinoma. Alternatively, if you would like to view where your term fits in ...
Papillary serous cystadenocarcinomaMucinous cystadenocarcinomaCystadenomaCarcinomaAdenocarcinomaDysgerminoma and serous cystadenocarcinomaPancreaticTumorsNeoplasmsFollowed by mucinousHigh-grade serousCommonest benign tumourCystadenocarcinomasCysticTumoursCystadenomasCancersNeoplasticFoundCase reportTreatmentPresentAdenocarcinomaPancreaticEndometrioidTumorPeritonealCystadenocarcinomasBenignHGSOCMalignant ovarianCancerCaseArticleType
Papillary serous cystadenocarcinoma3
- Combination of papillary serous cystadenocarcinoma and dysgerminoma was yet to be reported. (banglajol.info)
- Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. (bvsalud.org)
- Nagar YS , Singh S , Sawlani V , Pal L , Dimri K , Lal P . Primary papillary serous cystadenocarcinoma of broad ligament . (autopsyandcasereports.org)
Mucinous cystadenocarcinoma5
- Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (ucbraid.org)
- Mucinous cystadenocarcinoma is the second most common etiology of appendiceal mucocele. (biomedcentral.com)
- We report a relatively rare case of a giant appendiceal mucocele caused by mucinous cystadenocarcinoma, which occupied the entire abdomen of an adult woman. (biomedcentral.com)
- There were 28.4% serous cystadenoma, 21% mucinous cystadenoma, 6.2% intraductal papillary tumors, 8.6% solid pseudopapillary tumors, 1.2% neuroendocrinal tumor, 3.7% ductal adenocarcinoma, and 30.9% mucinous cystadenocarcinoma. (saudijgastro.com)
- Histology reported a mucinous cystadenocarcinoma of low malignant potential. (medscape.com)
Cystadenoma3
- The commonest benign tumor was serous cystadenoma(40/66) followed by dermoid cyst(12/66). (ijcrr.com)
- The commonest benign tumour was serous cystadenoma and malignant was serous cystadenocarcinoma. (ijcrr.com)
- serous tumors (including serous cystadenoma (SCA) and cystadenocarcinoma), mucinous tumors (including mucinous cystadenomas (MCN), mucinous cystadenocarcinomas, intraductal papillary adenomas, and intraductal papillary adenocarcinoma) and solid pseudopapillary tumors (SPT). (saudijgastro.com)
Carcinoma3
- This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC. (clinicaltrials.gov)
- Serous cystadenocarcinoma was the commonest malignant tumour followed closelyby endometrioid carcinoma and granulosa cell tumour. (edu.pk)
- Hemalatha AL , Rao SM , Kumar DB , Vani M . Papillary serous carcinoma of the broad ligament: a rare case report . (autopsyandcasereports.org)
Adenocarcinoma1
- There are no common causative somatic gene mutations, outside of TP53 alterations in serous adenocarcinoma and KRAS, BRAF and PTEN in mucinous, endometrioid, and low grade serous cancers, suggested to be associated with the pathogenesis of EOC [ 2 ]. (oncotarget.com)
Dysgerminoma and serous cystadenocarcinoma2
- Microscopically it was diagnosed as a collision tumor of ovary composed of dysgerminoma and serous cystadenocarcinoma. (banglajol.info)
- Sengupta S, Pal S, Biswas B, Chakrabarti S, Bose K, Jana S. Collision tumor of ovary: a rare combination of dysgerminoma and serous cystadenocarcinoma. (who.int)
Pancreatic1
- The most common pancreatic cysts were serous and mucinous cysts. (saudijgastro.com)
Tumors1
- Serous cystadenomas are benign epithelial tumors seen in the 4th to 5th decade. (appliedradiology.com)
Neoplasms1
- They are larger than serous neoplasms, with a "honey-comb" of locules with varied signal intensities separated by thin septations and no solid components. (appliedradiology.com)
Followed by mucinous1
- The commonest malignant tumour was serous cystadenocarcinoma (5/16) followed by mucinous cystadenocarcinomama (3/16). (ijcrr.com)
High-grade serous3
- Our comparison of copy-number changes, mutations and mRNA expression profiles reveals pronounced differences in molecular profiles between commonly used ovarian cancer cell lines and high-grade serous ovarian cancer tumour samples. (nih.gov)
- Genetic and immunophenotype analyses have shown that high-grade serous ovarian cancer, the most frequent histological type and the one with the worst prognosis, originates mainly from fallopian tube epithelium, while endometrioid and clear-cell cancers originate from the endometrium. (viamedica.pl)
- In particular, we would like to alert researchers to the fact that the most popular cell lines SKOV3 and A2780 do not represent a suitable model for studies on high-grade serous ovarian cancer. (viamedica.pl)
Commonest benign tumour1
- Benign serous cysts were the commonest benign tumour followed by mature cystic teratomaand mucinous cyst. (edu.pk)
Cystadenocarcinomas1
- Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (nih.gov)
Cystic1
- The cystic mass contained about 7000 mL of serous fluid. (biomedcentral.com)
Tumours1
- There was no significant increase in serous tumours, a modest increase in mucinous tumours, but a substantial increase in endometrioid (RR = 1.49, 95% CI: 1.18-1.89) and clear-cell tumours (RR = 1.68, 1.29-2.20). (ox.ac.uk)
Cystadenomas1
- Two types of hepatic cystadenomas are described pathologically, as follows: mucinous and serous. (medscape.com)
Cancers4
- L'objectif de cette étude était de déterminer la fréquence des cancers gynécologiques en pratique oncologique à Lomé et d'en étudier les aspects épidémiologiques et histo-cliniques. (bvsalud.org)
- Il s'agitd'une étude rétrospective et descriptive portant sur tous les cancers gynécologiques reçus en oncologie entre le 1erJanvier 2016 et le 31 Décembre 2021. (bvsalud.org)
- ces cancers ont ete diagnostiques au stade avance d'ou les difficultes dans leur prise en charge chirurgicale. (bvsalud.org)
- En consequence notre objectif a ete d'etudier la place et les caracteres de la chirurgie dans la prise en charge de ces cancers. (bvsalud.org)
Neoplastic1
- The commonest non-neoplastic lesion was Luteal cyst (43/104) followed by simple serous cyst (25/104). (ijcrr.com)
Found1
- No article was found for Cystadenocarcinoma, Serous and TERT[original query] . (cdc.gov)
Case report1
- Mrad K , Driss M , Abdelmoula S , Sassi S , Hechiche M , Ben Romdhane K . Primary broad ligament cystadenocarcinoma with mucinous component: a case report with immunohistochemical study . (autopsyandcasereports.org)
Treatment1
- Improper treatment, such as marsupialization, internal Roux-en-Y drainage, or percutaneous drainage and alcoholization, is associated with almost certain recurrence. (medscape.com)
Present1
- The present case is the largest appendiceal cystadenocarcinoma ever reported. (biomedcentral.com)
Adenocarcinoma2
- Isoprenaline and aminophylline may not take the drug is poorly absorbed orally and as injection 160 mg/ml for injection, excessive irradiation of malignant ovarian tumors surface epithelial tumors serous cystadenoma serous cystadenocarcinoma mucinous cystadenoma mucinous adenocarcinoma endometrioid borderline epithelial tumor brenner tumor larger masses can be antagonised by adrenaline. (ceu.edu)
- According to recent study results, MASCs also mimic other salivary gland tumors, including adenocarcinoma, not otherwise specified (ANOS), mucoepidermoid carcinoma (MEC), and cystadenocarcinoma (CAC). (jpatholtm.org)
Pancreatic1
- Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. (uci.edu)
Endometrioid1
- Another research demonstrated that YAP1 is normally portrayed in serous/endometrioid cystadenocarcinomas extremely, and is favorably connected with individual prognosis (16). (pik-93.info)
Tumor4
- The aim of this study was to assess the outcomes of the largest series of patients treated conservatively for a stage II or III serous borderline ovarian tumor. (nih.gov)
- From 1969 to 2006, 41 patients were treated conservatively for an advanced-stage serous borderline ovarian tumor. (nih.gov)
- All patients with serous cystadenocarcinomas and serum CA 125 values of 20-35 u/ml had residual tumor, and two-thirds of these cases had grossly visible disease. (elsevier.com)
- Serous cystadenocarcinoma with inltrating cords of tumor cells with prominent dissolution of tumor. (tetratherapeutics.com)
Peritoneal2
- More than 90% of fallopian tube cancers are serous adenocarcinomas, which are histologically indistinguishable from papillary serous ovarian carcinoma ( 4, 5 ), so they must be defined morphologically by the invasion of the peritoneal surfaces with minimal or no involvement of the ovaries ( 6 ). (aacrjournals.org)
- Psammocarcinoma is a rare form of serous ovarian and peritoneal carcinoma, characterized by abundant psammoma bodies, invasiveness, and low-grade cytological features. (omeka.net)
Cystadenocarcinomas1
- Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (bvsalud.org)
Benign2
- In the cystadenomas and areas consisting of benign-appearing cells in the cystadenocarcinoma , CEA was localized to the luminal surfaces of the glandular cells appearing as thin linear stains. (lookfordiagnosis.com)
- For patients with malignant ovarian disease, this study was limited to serous papillary adenocarcinomas and women with benign ovarian disease were limited to serous adenoma. (congresoendocrinologia2016.com)
HGSOC3
- High-grade serous ovarian carcinoma (HGSOC) accounts for most ovarian cancer cases, and it is most frequently diagnosed at advanced stages. (aacrjournals.org)
- High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer and is the cause of approximately 70% to 80% of all ovarian cancer deaths ( 2, 3 ). (aacrjournals.org)
- Therefore, the aim of the present study was to comparatively examine expression of notable immune co‑stimulatory and co‑inhibitory receptors in order identify the most abundant receptors that could potentially serve as therapeutic targets to enhance immunotherapy response in high grade serous ovarian cancer (HGSOC). (spandidos-publications.com)
Malignant ovarian1
- Nevertheless, the function of YAP1 as an oncogene hasn't yet been completely investigated in a big band of ovarian serous cystadenocarcinoma (OSC) sufferers, who take into account the biggest percentage of malignant ovarian cancers situations (17,18). (pik-93.info)
Cancer4
- FOXM1 and RHNO1 are both amplified and upregulated in high-grade serous ovarian cancer (HGSC). (biorxiv.org)
- Is Trametinib a New Standard for Low-Grade Serous Ovarian Cancer? (medscape.com)
- En 11 annees (1er janvier 1998-31 decembre 2008) 9946 patientes ont ete operes dans notre servie dont 29 pour le cancer de l'ovaire soit 0;29. (bvsalud.org)
- Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. (uams.edu)
Case1
- The interactive module below presents a case of ovarian serous cystadenocarcinoma through pre- and post-operative contrast-enhanced CT as well as a 3D reconstruction. (medscape.com)
Article1
- No article was found for Cystadenocarcinoma, Serous and KIR3DP1[original query] . (cdc.gov)
Type1
- Serous carcinomas were the most commonly diagnosed histologic type for all anatomic sites. (aacrjournals.org)